Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

Creams: SOP for Reporting and Managing Out-of-Specification (OOS) Results – V 2.0

Posted on By

Creams: SOP for Reporting and Managing Out-of-Specification (OOS) Results – V 2.0

Standard Operating Procedure for Reporting and Managing Out-of-Specification (OOS) Results

Department Creams
SOP No. SOP/CRM/155/2025
Supersedes SOP/CRM/155/2022
Page No. Page 1 of 6
Issue Date 21/01/2026
Effective Date 26/01/2026
Review Date 21/01/2027

1. Purpose

The purpose of this SOP is to define the process for reporting and managing Out-of-Specification (OOS) results in QC testing of cream formulations. The procedure ensures that any deviations from specified standards are properly documented, investigated, and addressed to maintain product quality and compliance with regulatory requirements.

2. Scope

This SOP applies to all cream formulations manufactured at the facility that are subject to QC testing. It covers the process for identifying, reporting, investigating, and resolving OOS results for critical tests, such as viscosity, pH, microbial counts, and active ingredient content.

3. Responsibilities

  • Quality Control (QC) Team: Responsible for identifying and reporting OOS results during testing. QC personnel must initiate investigations, identify potential root causes, and document all findings.
  • Quality Assurance (QA) Team: Responsible for reviewing OOS results, overseeing investigations, and ensuring that corrective and preventive actions (CAPA) are taken. QA must ensure that the process is compliant with regulatory requirements.
  • Production Team: Responsible for providing information related
to the manufacturing process, which may assist in the investigation of OOS results. The team may need to implement corrective actions to prevent future occurrences.
  • Management Team: Responsible for reviewing and approving final investigation reports, ensuring that appropriate actions are taken to prevent recurrence of OOS results.
  • 4. Accountability

    The QC Manager is accountable for ensuring that OOS results are identified, reported, and investigated in a timely manner. The QA Manager is responsible for overseeing the investigation process, ensuring compliance with GMP, and approving final investigation reports and corrective actions. The Production Manager is responsible for implementing corrective actions within the production process.

    5. Procedure

    5.1 Identifying and Reporting OOS Results

    1. QC personnel must immediately report any test results that fall outside the specified limits to the QC Manager and the QA Team.
    2. The OOS result should be recorded in the OOS Log (Annexure-1), including the test type, sample details, test date, result, and the specification limits.
    3. The individual responsible for the test must sign off on the OOS result to confirm the observation and initiate the reporting process.

    5.2 Investigating OOS Results

    1. Upon identifying an OOS result, an investigation should be initiated to determine whether the OOS was due to testing error, equipment malfunction, or an actual deviation in the product quality.
    2. Investigate the following potential causes:
      • Sampling errors
      • Instrument malfunction or improper calibration
      • Operator errors during testing
      • Deviations in the manufacturing process (e.g., ingredient addition, mixing, storage conditions)
      • Issues with raw materials or packaging components
    3. The investigation should include a review of batch records, equipment calibration logs, and testing procedures to identify any discrepancies or anomalies.
    4. Document the investigation process, including the root cause analysis, in the OOS Investigation Report (Annexure-2).

    5.3 Corrective and Preventive Actions (CAPA)

    1. Once the root cause of the OOS result has been identified, the appropriate corrective actions must be implemented to resolve the issue and prevent recurrence.
    2. Corrective actions may include:
      • Re-running the test with a new sample or re-sampling the product
      • Calibrating or repairing equipment
      • Retraining personnel on testing procedures
      • Adjusting the manufacturing process if needed
    3. Preventive actions should also be taken to address any systemic issues, such as revising SOPs, improving quality checks, or enhancing training programs.
    4. Document all corrective and preventive actions in the CAPA Log (Annexure-3). Ensure that each action is tracked for completion and effectiveness.

    5.4 Final Review and Reporting

    1. Once the investigation is completed, and corrective and preventive actions have been implemented, the investigation report and CAPA should be reviewed by the QA Manager and senior management.
    2. If the OOS result is determined to be valid, the product batch in question should be re-assessed to determine whether it can be released for distribution or requires rework or rejection.
    3. Document the final decision regarding the OOS result, including the product status and any actions taken, in the Final OOS Report (Annexure-4).
    4. Ensure that all documentation is retained for a minimum of two years or as required by regulatory guidelines.

    5.5 Documentation and Record-Keeping

    1. Ensure that all OOS results, investigations, CAPAs, and final reports are properly documented and securely stored. These records include the OOS Log (Annexure-1), OOS Investigation Report (Annexure-2), CAPA Log (Annexure-3), and Final OOS Report (Annexure-4).
    2. Retain all records for the required duration as per regulatory guidelines (typically two years or as required by local regulations).
    3. Ensure that records are reviewed and approved by the Quality Assurance team to ensure compliance with GMP standards and regulatory requirements.

    6. Abbreviations

    • GMP: Good Manufacturing Practices
    • QC: Quality Control
    • QA: Quality Assurance
    • PPE: Personal Protective Equipment
    • OOS: Out-of-Specification
    • CAPA: Corrective and Preventive Actions

    7. Documents

    1. Annexure-1: OOS Log
    2. Annexure-2: OOS Investigation Report
    3. Annexure-3: CAPA Log
    4. Annexure-4: Final OOS Report

    8. References

    • Good Manufacturing Practices (GMP) Guidelines – 21 CFR Part 211
    • International Conference on Harmonisation (ICH) Q7 – Good Manufacturing Practice for Active Pharmaceutical Ingredients
    • FDA Guidance for Industry: Investigating Out-of-Specification Results

    9. SOP Version

    Version: 2.0

    10. Approval Section

    Prepared By Checked By Approved By
    Signature
    Date
    Name
    Designation
    Department

    11. Annexures

    Annexure-1: OOS Log

    Batch Number Test Type Test Date OOS Result Specification Operator
    12345 Viscosity 21/01/2026 Out of Range 50-100 cP John Doe

    Annexure-2: OOS Investigation Report

    Batch Number Investigation Date Root Cause Corrective Action Operator
    12345 22/01/2026 Equipment calibration error Recalibrated equipment and retested Jane Smith

    Annexure-3: CAPA Log

    CAPA ID Action Date Corrective Action Taken Preventive Action Taken Follow-Up Date
    CAPA-001 23/01/2026 Recalibrated viscometer Revised calibration procedure 26/01/2026

    Annexure-4: Final OOS Report

    Batch Number Final Decision Action Taken Approved By
    12345 Pass after recalibration Recalibrated and retested QA Head

    Revision History:

    Revision Date Revision No. Revision Details Reason for Revision Approved By
    01/03/2024 1.0 Initial Version New SOP Creation QA Head
    01/03/2025 2.0 Format Revision and Updates Standardization of Document QA Head
    See also  Creams: SOP for Conducting Heavy Metal Testing in Creams - V 2.0
    Creams V 2.0 Tags:Batch record documentation for creams, Change control procedures for cream manufacturing, Cleaning and sanitization SOPs in creams production, Complaint handling SOPs in creams production, Continuous improvement SOPs for cream manufacturing, Cream manufacturing process guidelines, Creams production documentation practices, Deviation handling SOPs in creams production, Employee training SOPs in creams manufacturing, Environmental monitoring SOPs in creams manufacturing, Equipment calibration SOPs for cream manufacturing, GMP compliance in creams production, Internal audit procedures in creams production, Packaging and labeling SOPs for creams, Pharmaceutical SOPs, Product quality review procedures for creams, Product release criteria SOPs for creams, Quality control SOPs for creams, ream manufacturing SOP, Regulatory requirements for cream production SOPs, Risk management SOPs in creams manufacturing, Stability testing SOPs for cream products, Standard operating procedures for skincare products, Supplier qualification SOPs for cream ingredients, Validation protocols for cream production processes

    Post navigation

    Previous Post: Biosimilars: SOP for Foam Sensor Calibration in Bioreactor Systems – V 2.0
    Next Post: API Manufacturing: SOP for Preparation and Storage of Working Standards – V 2.0

    Standard Operating Procedures V 1.0

    • Aerosols
    • Analytical Method Development
    • Bioequivalence Bioavailability Study
    • Capsule Formulation
    • Clinical Studies
    • Creams
    • Data Integrity
    • Dental Dosage Forms
    • Drug Discovery
    • Environment, Health and Safety
    • Formulation Development
    • Gels
    • Good Distribution Practice
    • Good Warehousing Practices
    • In-Process Control
    • Injectables
    • Liquid Orals
    • Liposome and Emulsion Formulations
    • Lotions
    • Lyophilized Products
    • Maintenance Dept.
    • Medical Devices
    • Metered-Dose Inhaler
    • Microbiology Testing
    • Nanoparticle Formulation
    • Nasal Spray Formulations
    • Nebulizers
    • Ocular (Eye) Dosage Forms
    • Ointments
    • Otic (Ear) Dosage Forms
    • Pharmacovigilance
    • Powder & Granules
    • Purchase Departments
    • Quality Assurance
    • Quality Control
    • Raw Material Stores
    • Regulatory Affairs
    • Tablet Manufacturing
    • Rectal Dosage Forms
    • Transdermal Patches
    • Vaginal Dosage Forms
    • Validations and Qualifications

    Read SOPs in your Language:

     - 
    Bengali
     - 
    bn
    English
     - 
    en
    Gujarati
     - 
    gu
    Hindi
     - 
    hi
    Malayalam
     - 
    ml
    Marathi
     - 
    mr
    Punjabi
     - 
    pa
    Tamil
     - 
    ta
    Telugu
     - 
    te

    NEW! Revised SOPs – V 2.0

    • Aerosols V 2.0
    • Analytical Method Development V 2.0
    • API Manufacturing V 2.0
    • BA-BE Studies V 2.0
    • Biosimilars V 2.0
    • Capsules V 2.0
    • Creams V 2.0
    • Elixers V 2.0
    • Ointments V 2.0
    • Raw Material Warehouse V 2.0
    • Tablet Manufacturing V2.0

    New Publication: A must for All.

    Copyright © 2025 SOP Guide for Pharma.

    Powered by PressBook WordPress theme

    Go to mobile version